Grounded in the literature.
Delivered with restraint.
Our protocols reference contemporary endocrinology, metabolic medicine and longevity research. We publish the reasoning behind each therapy in plain language — no hype, no shortcuts, no claims we cannot defend.
Four commitments that shape every protocol.
Individual before intervention
Every plan starts with the specific patient — labs, symptoms, history, life stage — before any medication enters the conversation.
Titrate, don't guess
Doses are set to physiologic response, not marketing anchors. Titration is planned in advance, not improvised in the moment.
Monitor what matters
Surveillance panels are chosen for clinical relevance. We do not chase incidental findings or over-order labs for optics.
De-escalate when appropriate
The goal is the outcome, not the prescription. Where a plan can be simplified, shortened or paused, it is.
Where we sit on the evidence curve.
We prescribe therapies that clear a defined bar: an established mechanism, a favorable risk-benefit profile in appropriate candidates, and a monitoring pathway our providers can execute reliably.
We are early on some longevity-adjacent protocols and conservative on others. That reasoning is published in the Journal so members can hold us to it.
The lines we hold.
- 01Prescribe without provider review and, where indicated, laboratory data.
- 02Recommend a therapy the peer-reviewed evidence does not yet support in the intended population.
- 03Sell a monitoring cadence heavier than the clinical picture actually requires.
- 04Overstate outcomes, trade in miracle language or promise results we cannot defend.